PureTech Health PLC PureTech's Vedanta Granted European Patent (8879M)
19 October 2016 - 5:00PM
UK Regulatory
TIDMPRTC
RNS Number : 8879M
PureTech Health PLC
19 October 2016
19 October 2016
PureTech Health plc
PureTech Health's Vedanta Biosciences Granted European Patent
Broadly Covering Pharmaceutical Compositions for Microbiome
Therapeutics Based on Bacterial Consortia
PureTech Health plc (LSE: PRTC), a cross-disciplinary biotech
company developing 21(st) century medicines, is pleased to note
that the European Patent Office (EPO) has issued European Patent
EP2575835 that broadly covers pharmaceutical compositions of
Clostridium live bacterial strains. This European Patent is Vedanta
Biosciences' latest addition to their patent portfolio after the
issuances of three U.S. patents in the previous months and earlier
issuances in Japan. These patents are exclusively licensed to
Vedanta Biosciences under an agreement with the University of Tokyo
and provide coverage through at least 2031. The patent issuance
also triggers another milestone payment of $2 million from Janssen
Biotech, Inc. as part of Vedanta's ongoing collaboration for a
product candidate in inflammatory bowel disease. Vedanta has a
broad platform and multiple other product candidates outside of
this collaboration.
Daphne Zohar, Co-Founder and Chief Executive Officer at PureTech
Health, said: "We are pleased to receive our first European patent
in the microbiome area, which combined with our three U.S. patents,
further strengthens our global intellectual property leadership
position in the microbiome. The patent has broad, fundamental
claims that we believe will be important for the commercialisation
of microbiome therapeutics based on bacterial consortia."
The full text of the announcement from Vedanta Biosciences is as
follows:
Vedanta Biosciences Granted First European Patent Broadly
Covering Pharmaceutical Compositions for Microbiome Therapeutics
Based on Bacterial Consortia
CAMBRIDGE, Massachusetts, October 19, 2016 - Vedanta
Biosciences, pioneering the development of a novel class of
therapies for immune and infectious diseases based on rationally
designed consortia of bacteria derived from the human microbiome,
today announced that the European Patent Office (EPO) has issued
European Patent EP2575835. The patent broadly covers pharmaceutical
compositions of Clostridium live bacterial strains and further
expands Vedanta Biosciences' patent portfolio after the issuances
of three U.S. patents in the previous months and earlier issuances
in Japan. The patents are exclusively licensed to Vedanta
Biosciences under an agreement with the University of Tokyo and
provide coverage through at least 2031.
The patented technology is based on ground-breaking work by Dr.
Kenya Honda, a scientific co-founder of Vedanta Biosciences. Dr.
Honda's work provides an avenue for the treatment of a variety of
diseases including immune and infectious diseases employing
bacterial strains belonging to Clostridium clusters IV and/or XIVa.
Clostridium bacteria include a variety of spore-forming species
that can abundantly colonise the gut.
"This European patent is an important addition to our global
intellectual property portfolio," said Bernat Olle, Ph.D., Chief
Executive Officer of Vedanta Biosciences. "The claims issued put
Vedanta in a very favourable position to commercialise drugs based
on bacterial consortia in the second largest market in the world."
said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta
Biosciences.
About Vedanta Biosciences
Vedanta Biosciences is pioneering development of a novel class
of therapies for immune and infectious diseases based on rationally
designed consortia of bacteria derived from the human microbiome,
with clinical trials expected to begin in the first half of 2017.
Founded by PureTech Health (PureTech Health plc, PRTC.L) and a
group of world-renowned experts in immunology and microbiology,
Vedanta Biosciences is a leader in the microbiome field with
capabilities to discover, develop and manufacture drugs based on
live bacterial consortia. Leveraging its proprietary technology
platform and the expertise of its team of scientific cofounders,
Vedanta Biosciences has isolated a vast collection of
human-associated bacterial strains and characterised how the immune
system recognises and responds to these microbes. This work has led
to the identification of human commensal bacteria that induce a
range of immune responses - including induction of regulatory T
cells and Th17 cells, among others - as well as the
characterisation of novel molecular mechanisms of microbial-host
communication. These advances have been published in leading
peer-reviewed journals including Science, Nature (multiple), Cell
and Nature Immunology. Vedanta Biosciences has harnessed these
biological insights as well as data from clinical translational
collaborations to generate a pipeline of programs in development
for infectious disease, autoimmune disease, inflammation and
immune-oncology. The clinical potential of therapeutic manipulation
of the microbiome has been validated by multiple randomised,
controlled trials in infectious disease and inflammatory bowel
disease.
Vedanta Biosciences' scientific co-founders have pioneered the
fields of innate immunity, Th17 and regulatory T cell biology, and
include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale),
Dr. Alexander Rudensky (tri-institutional Professor at the Memorial
Sloan-Kettering Institute, the Rockefeller University and Cornell
University), Dr. Dan Littman (Professor of Molecular Immunology at
NYU), Dr. Brett Finlay (Professor at the University of British
Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio
University).
PureTech Health plc (PRTC.L) owns 75.4% of Vedanta on a diluted
basis as of 30 June 2016. This calculation includes issued and
outstanding shares as well as options to purchase shares and
written commitments to issue shares or options, but excludes
unallocated shares authorised to be issued pursuant to equity
incentive plans.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary biotech company creating 21(st) century
medicines that modulate the adaptive human systems. Our therapies
target the immune, nervous, and gastro-intestinal systems by
addressing the underlying pathophysiology of disease across
multiple dimensions rather than through a single receptor or
pathway. We are advancing more than 20 clinical studies across our
pipeline, with five human proof-of-concept studies and multiple
pivotal or registration studies expected to read out in the next
two years. PureTech Health's pipeline is sourced and filtered by
the world's leading scientific experts, who along with PureTech's
leading team and board analyse more than 650 scientific discoveries
per year to identify the most promising opportunities for patients.
This process places the PureTech Health on the cutting edge of
ground-breaking science and technological innovation and leads the
Company between and beyond existing disciplines. For more
information, visit www.puretechhealth.com or connect with us on
Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Enquiries
PureTech
Allison Mead, Director, Communications +1 617 651
and Investor Relations 3156
FTI Consulting (Communications adviser
to PureTech)
Ben Atwell +44 (0) 20
Matthew Cole 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUWSWRNRARAAA
(END) Dow Jones Newswires
October 19, 2016 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024